Measurement of the effects of foods containing processed whey protein on metabolism in healthy subjects - Measurement of the effects of foods containing processed whey protein on metabolism in healthy subjects

Start Date03 Jun 2024

Sponsor / Collaborator

Hirosaki University

JPRN-UMIN000052252 / SuspendedIIT

Examining the association between mitochondrial dysfunction and indeterminate physical complaints - Mitochondrial dysfunction and indeterminate physical complaints

Start Date16 Oct 2023

Sponsor / Collaborator

Hirosaki University

JPRN-UMIN000053070 / CompletedNot ApplicableIIT

Research on the physical abilities, activity patterns, and mental and physical health of the elderly using wearable devices - Research on the physical abilities, activity patterns, and mental and physical health of the elderly using wearable devices

Start Date08 Sep 2023

Sponsor / Collaborator

Hirosaki University

100 Clinical Results associated with Hirosaki University

0 Patents (Medical) associated with Hirosaki University

18,392

Literatures (Medical) associated with Hirosaki University

01 Feb 2025·Separation and Purification Technology

Fabrication of indium doped Bi/Bi2O3 catalyst for efficiently selective electroreduction of carbon dioxide to formate

Author: Ramli, Yusrin ; Hao, Xiaogang ; Feng, Zhongbao ; An, Xiaowei ; Wang, Junli ; Feng, Changrui ; Abudula, Abuliti ; Lu, Houfang ; Yang, Ziyuan ; Li, Shasha ; Guan, Guoqing ; Wang, Peifen

Highly selective electrocatalytic reduction of CO₂ to formate is considered a valid route for alleviating the continuing increase in atm. CO₂ concentrationHerein, Indium-doped Bi/Bi₂O₃ (In-Bi/Bi₂O₃) electrocatalyst grown in situ on carbon paper (CP) was obtained via a relatively simple one-step solvothermal synthesis method and utilized in CO₂ reduction reaction (CO₂RR) for formate productionThe In-Bi/Bi₂O₃/CP exhibits superior Faradaic Efficiency for formate, i.e., FE_formate = 96.3 %, and a partial c.d. of 6.74 mA cm^-2 at -1.6 V (vs Ag/AgCl) in the H-type cell.Furthermore, FE_formate of the electrode remains consistently above 90 % within long-term stability testing (60 h).By d. functional theory (DFT) calculations, it is found that incorporating In into Bi/Bi₂O₃ can generate more active sites and facilitate the preferential adsorption of *OOCH intermediates, alleviating competitive adsorption of *H during CO₂ reduction reaction (CO₂RR), thereby accelerating formate production

01 Jan 2025·Journal of Colloid and Interface Science

Modulation of charge structure in Bi/Bi2O3-In2O3@C for efficient CO2 electroreduction to formate

Article

Author: An, Xiaowei ; Feng, Changrui ; Zhang, Pan ; He, Yang ; Feng, Zhongbao ; Gao, Bo ; Yang, Ziyuan ; Abudula, Abuliti ; Guan, Guoqing ; Fu, Yumo

Electrocatalytic CO₂ reduction reaction (ECO₂RR) to value-added chemicals is of significant importance to control CO₂ emission and reach carbon neutrality. Herein, Bi/Bi₂O₃-In₂O₃@C electrocatalyst with nanosheet arrays is successfully fabricated by a facile solvothermal with subsequent calcination process. It is found that the electron structure of Bi/Bi₂O₃-In₂O₃@C can be adjusted by the synergistic effects of Bi-In hetero-diatoms, which can significantly enhance its inherent catalytic activity. As expected, it requires a maximum HCOOH faradaic efficiency (FE_HCOOH) of 97.6 % at -1.1 V vs. Reversible Hydrogen Electrode (RHE), which further delivers over 90 % at a wide potential range of -0.8 to -1.4 V vs. RHE, and exhibits high stability of 90.1 % over 60-h long-term test. In-situ Raman analysis is performed to explore the mechanism of its excellent stability. Meanwhile, in-situ attenuated total reflection-Fourier-transform infrared (ATR-FTIR) analysis combined with theoretical calculations reveal that the hetero-bridging absorption of *OCHO and d-d orbital coupling effect can regulate d-band center of Bi/Bi₂O₃-In₂O₃@C and improve its density of states around E_f, moderating free energy of intermediates, thereby the improved formate production performance can be seen.

01 Dec 2024·Archives of Gerontology and Geriatrics

Bidirectional causal associations between aging and major mental disorders: A population-based study using the two-sample mendelian randomization method from the UK biobank (AM-SRNMA 002)

Article

Author: Huang, Wenbo ; Liu, Mingxin ; Lin, Cheng

AIMSWhile observational studies have suggested associations linking aging and mental disorders, the question of causality has remained unclear. This study aimed to explore the causal relationship between aging level and major mental disorders.METHODSWe utilized Two-Sample Mendelian randomization (2SMR) with mental disorders data and aging indicators information from an extensive genome-wide association study (GWAS) database. The GWAS database is a comprehensive resource that compiles genetic association data, encompassing a sample size of over 450,000 individuals. We employed five methods for 2SMR and single nucleotide polymorphisms were chosen as instrumental variables.RESULTSOur analyses consistently supported a bidirectional causal association between the Frailty Index (FI) and Major Depressive Disorder (MDD). Furthermore, our findings indicated potential influences, such as Attention-Deficit/Hyperactivity Disorder (ADHD) and Bipolar Disorder (BD) affecting GrimAge, and Anxiety Disorder (AD) impacting Left Hand Grip Strength (LHGS). In contrast, we observed no significant correlations for other mental disorders on FI, Telomere Length (TL), GrimAge, Appendicular Lean Mass (ALM), and LHGS. In the reverse direction, FI showed a significant impact on the risk of MDD, AD, and ADHD, while LHGS affected the risk of MDD. Importantly, no significant associations were found between other factors and the risk of MDD, BD, AD, Schizophrenia (SZ), and ADHD.CONCLUSIONSThis 2SMR analysis has presented evidence for a bidirectional causal relationship between FI and MDD, while the relationship between ADHD, BD, and GrimAge should be more considered. Our study provides genetic evidence supporting a causal link between aging indicators and several mental illnesses.

News (Medical) associated with Hirosaki University

07 Oct 2021

·www.nsmedicaldevices.com

Asensus Surgical Announces Hirosaki University Hospital to Initiate Senhance Robotic Surgery Programme

Asensus Surgical's technology platform, Senhance Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning Asensus Surgical Announces Hirosaki University Hospital to Initiate Senhance Robotic Surgery Programme. (Credit: Sasin Tipchai from Pixabay) Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced Hirosaki University Hospital has entered into an agreement to lease and utilize a Senhance® Surgical System. “We are excited to add a system at Hirosaki University Hospital to help build out its Senhance Robotic Surgery Program,” said Anthony Fernando, Asensus Surgical President and CEO. “We are very encouraged by the continued momentum we are seeing in Japan and look forward to further expanding our footprint in the region.’’ Asensus Surgical’s technology platform, Senhance Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning. Senhance goes beyond the typical surgical robotic systems, providing surgical assurance through haptic feedback, eye-tracking camera control, and 3D visualization, and is the first platform to offer 3 mm instruments (the smallest instrument available in the world on a robotic surgical platform). The Senhance Surgical System is powered by the Intelligent Surgical Unit™ (ISU™). The ISU enables machine vision-driven control of the camera for a surgeon by responding to commands and recognizing certain objects and locations in the surgical field, and allows a surgeon to change the visualized field of view using the movement of their instruments. The newest ISU features expand upon these capabilities and introduce more advanced features including: 3D measurement, digital tagging, image enhancement, and enhanced camera control based on real-time data from anatomical structures while performing surgery. “The initiation of the Senhance program contributes to our emphasis on the delivery of innovative medicine,” said Dr. Kenichi Hakamada, Professor and Chairman, Department of Gastroenterological Surgery Department of Pediatric Surgery. “We look forward to exploring Senhance’s potential as a novel and differentiated treatment option for our patients, and as a powerful tool for our physicians.” Source: Company Press Release

100 Deals associated with Hirosaki University

100 Translational Medicine associated with Hirosaki University

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

PJ1-01 ( HMGB1 )	Osteoarthritis, Knee More	Phase 2

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis